Home › Core › ISCC-IDs › 28CrXPruGwnsy

View ISCC-ID

Core Data

28CrXPruGwnsy
ISCC-ID - digital asset identifier
CCAf55edF6xAQ-CTmjXQHJJqK1G-CDes3P8aiJcVw-CR4NJWY14nT5e
ISCC-CODE - digital asset descriptor
2QTa5N4aeSrCB2MLoPdPF4AsTjstJgcLTnd
PUBLIC-KEY or WALLET-ADDRESS of DECLARING PARTY
0
Number of times updated

Seed Metadata (Immutable)

adjunctive and longacting nanoformulated antiretroviral therapies for hivassociated neurocognitive disorders

Ledger Reference

coblo
Source Ledger/Blockchain
12361987
N-th ISCC Decleration on source ledger
67d7b8610dfba8920acf557d6a38a2c39b63825f814c457120d2a8628c90d716
Hash of block that includes the ISCC-DECLARATION
a5a0b13983850f1b9769f11381fe80fef2bd64d674ff9f292054b4a31cf30a13
Hash of transaction that includes the ISCC-DECLERATION
0
Output index that includes ISCC-DECLERATION (UTXO based chains)

Mutable Metadata

[{"data": {"name": "Adjunctive and long-acting nanoformulated antiretroviral therapies for HIV-associated neurocognitive disorders", "@type": "ScholarlyArticle", "genre": "journal-article", "author": [{"name": "Howard E. Gendelman", "@type": "Person"}, {"name": "Harris A. Gelbard", "@type": "Person"}], "@context": "http://schema.org/", "encoding": [{"@type": "MediaObject", "contentUrl": "http://europepmc.org/articles/pmc4231201?pdf=render", "encodingFormat": "application/pdf"}], "publisher": {"name": "Ovid Technologies (Wolters Kluwer Health)", "@type": "Organization"}, "identifier": [{"@type": "PropertyValue", "value": "10.1097/coh.0000000000000111", "propertyID": "DOI"}, {"@type": "PropertyValue", "value": "CCAf55edF6xAQ-CTmjXQHJJqK1G-CDes3P8aiJcVw-CR4NJWY14nT5e", "propertyID": "ISCC"}], "datePublished": "2014-11-01"}, "schema": "schema.org", "mediatype": "application/ld+json"}]
Close